4^th European Congress on Hematology and Blood Disorders

Dear Friends and Colleagues,

On behalf of the organizing committee, it is both an honor and a pleasure to announce the convening of the 4th European Congress on Hematology and Blood disorders in Vienna, Austria, from September 29^th to 30^th, 2025.

It is our primary objective for the meeting to bring together up-and-coming researchers to present up-to-date research results and clinical experiences in the spectrum of hematology and blood disorders.

Nothing will bring us more pleasure than seeing professional friends, young colleagues actively discussing their latest achievements, both basic and clinically applied.

We are excited to hold a face-to-face meeting again with structured lectures and discussions sharing knowledge and ideas with all researchers all over the world, and we will do it safely. Live academic meetings are historically known to be the best method for biologists, medical professionals and social scientists to gather and disseminate information, share new knowledge, and set new evidence-based policies and guidelines.

The conference will be held in Vienna, a major city in Europe rich in history that offers many options for trips in and around it.

Last but not least, please do not hesitate to contact us with your ideas or questions, which we value very much in our endeavor to continuously develop our specialties by creating a powerful voice for hematology, colleagues, and patients.

Prof. Jean Mercier Ythier

University of Paris Panthéon-Assas

Dear Friends and Colleagues,

On behalf of the organizing committee, it is both an honor and a pleasure to announce the convening of the Hematology Conference 2025 in Vienna, Austria from September 29- to September 30, 2025.

It is our primary objective for the meeting to bring together up-and-coming researchers to present up-to-date research results and clinical experiences in the spectrum of Hematology and Blood désordres.

Nothing will bring us more pleasure than seeing professional friends, young colleagues actively discussing their latest achievements, both basic and clinically applied.

We are excited to hold a face-to-face meeting again with structured lectures and discussions sharing knowledge and ideas with all researchers all over the world, and we will do it safely. Live academic meetings are historically known to be the best method for biologists, medical professionals and social scientists to gather and disseminate information, share new knowledge, and set new evidence-based policies and guidelines.

The conference will be held in Paris, a major city in Europe rich in history that offers many options for trips in and around it.

Last but not least, please do not hesitate to contact us with your ideas or questions, which we value very much in our endeavor to continuously develop our specialties by creating a powerful voice for hematology, colleagues, and patients.

Tamar Tadmor

Clinical Associate professor

Head of hematology unit and blood bank

Bnai-Zion Medical Center, Haifa, Israel

Hematology is a rapidly advancing field of science, over the past decade, many innovations and breakthroughs have occurred within this hematology and blood disorder diseases. Treatment protocols for hematological malignancies have grown progressively intricate; for instance, quadruplet treatments became known as the standard of care for multiple myeloma. Global access to hematopoietic stem-cell transplantation has enhanced, with an increase in centers established in low-income and middle-income countries (LMICs), and the development of optimized regimens to avoid and manage post-transplantation complications, including graft-versus-host disease. Innovative therapies have fundamentally transformed the way cancer is treated for hematological malignancies, including bispecific antibodies and CAR T cells. Current research is concentrated on extending this technology to solid tumors and rheumatological disorders, as well as creating more efficient and cost-effective production methods to enhance accessibility to these therapies. The initial gene therapies for sickle cell disease, thalassemia, and hemophilia have received approval, and novel, long-acting factor-replacement medications are transforming the lives of those with hemophilia. With all these advances, the theme for 4^th European Congress on Hematology and Blood Disorders is Hematology Evolution: Translating Discovery into Therapeutic Excellence.

       We are proud to have the honor of reporting and supporting these remarkable advancements by organizing academic events and bring professionals, doctors, clinicians, researchers and industries together in this field. Despite significant progress over the last decade, considerable obstacles remain. Reflecting on the past decade from a health viewpoint necessitates the inclusion of COVID-19. This global pandemic transformed the world, with repercussions still evident today. Numerous clinical trials encountered challenges in patient enrollment, which subsequently affected analysis. Worker burnout continues, and workforce shortages arise from insufficient specialization in classical hematology. Access to fundamental medicines, including hydroxyurea and factor VIII, in low- and middle-income countries is inadequate. The incorporation of COVID-19 is necessary when reflecting on the past decade from a health perspective. This global pandemic has had a lasting impact on the globe, with its repercussions still being felt. The analysis was subsequently impacted by the challenges that numerous clinical trials encountered in patient enrollment. Insufficient specialization in classical hematology has resulted in workforce shortages, and worker fatigue persists. In low- and middle-income countries, access to essential medications, such as factor VIII and hydroxyurea, is inadequate.
     We, the organizing committee of the 4^th European Congress on Hematology and Blood Disorders, have been privileged to connect with and support the community and conference. We express our gratitude to professionals, doctors, clinicians, researchers and industries for their ongoing enthusiasm and support of this conference.

Rui Wang

Suqian Affiliated Hospital of Xuzhou Medical University, China